FTI Consulting has appointed Christina Morris as a Senior Managing Director in its Healthcare Risk Management & Advisory practice. Based in Washington, D.C., Morris brings over 25 years of experience helping pharmaceutical and life sciences organisations modernise risk, regulatory compliance and quality operations through technology-enabled transformation. In her new role, Morris will work with clients to assess and modernise complex business processes using automation, data, AI and business process management. Her focus will be on strengthening compliance, reducing operational risk and improving audit readiness. Prior to joining FTI Consulting, Morris was a Managing Director at a Big Four firm, where she led technology-driven business transformation initiatives focusing on AI, GenAI and hyperautomation. She has also held senior positions at Hoverstate, FrontierBPM and EY.

FTI Consulting has appointed four managing directors to expand its turnaround and restructuring capabilities across the UK. James Bulloss joins from PwC with over 18 years' experience in restructurings and insolvencies. Kasey Lin arrives from Houlihan Lokey, bringing expertise in cross-border restructurings. Theo Kitsanelis, previously at Seabury Capital, will join the aviation practice. Matthew Mansell-Ahmed comes from Teneo with tax structuring expertise. The appointments form part of FTI Consulting's continued investment in its UK restructuring practice, following recent hires in London and Leeds. Matt Callaghan, head of UK turnaround and restructuring, said the new hires would enable the firm to deploy broader expertise on mandates across the country.

FTI Consulting reported second-quarter 2026 adjusted earnings of $2.16 per share, beating the Zacks Consensus Estimate of $2.09 by 3.4%. Earnings rose 1.4% year over year, whilst revenues increased 5.3%. Despite the earnings beat, FCN shares declined 4.1% following the 30 July release. The stock has fallen 6.4% over the past year. Net income dropped 19.4% to $57.8 million. Adjusted EBITDA fell 6.4% to $104.5 million as higher direct costs and SG&A expenses offset revenue growth. The adjusted EBITDA margin contracted 130 basis points to 10.5%. Corporate Finance revenues grew 8.5% to $411.4 million, driven by higher bill rates and increased transformation demand. Billable headcount across the firm increased 3.2%.